← Back to Screener
MiMedx Group, Inc (MDXG)
Price$3.25
Favorite Metrics
Price vs S&P 500 (26W)-56.61%
Price vs S&P 500 (4W)-26.60%
Market Capitalization$507.35M
P/E Ratio (Annual)10.44x
All Metrics
P/CF (Annual)6.86x
Book Value / Share (Quarterly)$1.73
P/TBV (Annual)4.14x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)16.06%
Cash Flow / Share (Quarterly)$0.49
Price vs S&P 500 (YTD)-53.70%
Gross Margin (TTM)82.56%
Net Profit Margin (TTM)11.60%
EPS (TTM)$0.32
10-Day Avg Trading Volume1.46M
EPS Excl Extra (TTM)$0.32
Revenue Growth (5Y)11.02%
EPS (Annual)$0.32
ROI (Annual)17.70%
Gross Margin (Annual)82.56%
Net Profit Margin (5Y Avg)5.32%
Cash / Share (Quarterly)$1.12
P/E Basic Excl Extra (TTM)10.44x
Revenue Growth QoQ (YoY)27.11%
P/E Normalized (Annual)10.44x
ROA (Last FY)14.18%
Revenue Growth TTM (YoY)19.99%
EBITD / Share (TTM)$0.43
ROE (5Y Avg)6.01%
Operating Margin (TTM)15.26%
Cash Flow / Share (Annual)$0.49
P/B Ratio1.98x
P/B Ratio (Quarterly)3.91x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)0.86x
Net Interest Coverage (TTM)77.70x
ROA (TTM)15.89%
EPS Growth QoQ (YoY)103.21%
EV / EBITDA (TTM)5.63x
EPS Incl Extra (Annual)$0.32
Current Ratio (Annual)4.32x
Quick Ratio (Quarterly)3.92x
3-Month Avg Trading Volume1.05M
52-Week Price Return-48.49%
EV / Free Cash Flow (Annual)4.92x
P/E Incl Extra (TTM)10.44x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.64
P/S Ratio (Annual)1.21x
Asset Turnover (Annual)1.22x
52-Week High$7.99
Operating Margin (5Y Avg)6.48%
EPS Excl Extra (Annual)$0.32
CapEx CAGR (5Y)-25.69%
Tangible BV CAGR (5Y)23.20%
26-Week Price Return-47.86%
Quick Ratio (Annual)3.92x
13-Week Price Return-39.98%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)4.32x
Enterprise Value$359.201
Revenue / Share Growth (5Y)4.06%
Asset Turnover (TTM)1.37x
Book Value / Share Growth (5Y)16.02%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.97x
Pretax Margin (Annual)15.83%
Cash / Share (Annual)$1.12
3-Month Return Std Dev39.35%
Gross Margin (5Y Avg)82.71%
Net Income / Employee (TTM)$0
ROE (Last FY)18.94%
Net Interest Coverage (Annual)8.59x
EPS Basic Excl Extra (Annual)$0.32
P/FCF (TTM)6.95x
Receivables Turnover (TTM)6.37x
EV / Free Cash Flow (TTM)4.92x
Total Debt / Equity (Quarterly)0.07x
EPS Incl Extra (TTM)$0.32
Receivables Turnover (Annual)6.37x
ROI (TTM)19.66%
P/S Ratio (TTM)1.21x
Pretax Margin (5Y Avg)5.34%
Revenue / Share (Annual)$2.80
Tangible BV / Share (Annual)$1.64
Forward P/E41.67x
Price vs S&P 500 (52W)-83.59%
P/E Ratio (TTM)10.44x
EPS Growth TTM (YoY)14.02%
Year-to-Date Return-49.56%
5-Day Price Return-12.88%
EPS Normalized (Annual)$0.32
ROA (5Y Avg)6.30%
Net Profit Margin (Annual)11.60%
Month-to-Date Return-13.54%
Cash Flow / Share (TTM)$0.01
EBITD / Share (Annual)$0.43
Operating Margin (Annual)15.26%
LT Debt / Equity (Annual)0.06x
P/CF (TTM)6.86x
ROI (5Y Avg)7.24%
P/E Excl Extra (TTM)10.44x
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$0.32
P/TBV (Quarterly)4.14x
P/B Ratio (Annual)3.91x
Inventory Turnover (TTM)2.97x
Pretax Margin (TTM)15.83%
Book Value / Share (Annual)$1.73
Price vs S&P 500 (13W)-42.85%
Beta1.57x
P/FCF (Annual)6.95x
Revenue / Share (TTM)$2.79
ROE (TTM)21.24%
52-Week Low$3.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.09
4.08
4.08
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
MDXGMiMedx Group, Inc | 1.21x | 11.02% | 82.56% | 15.26% | $3.25 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
MiMedx Group develops regenerative biomaterial products derived from human amniotic membrane and birth tissues for wound care, surgical, burn, orthopedic, and sports medicine applications. The company's core offerings include EpiFix and AmnioFix, flagship allografts that address external and internal wound healing needs across multiple surgical specialties. MiMedx also generates revenue through licensed partnerships for ophthalmic and dental applications.